Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 155

Sort by

Sort Order Select

Journal Articles

Early access program for danicopan (ALXN2040) as add-on treatment to eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH): Preliminary data from the Italian real-world survey.

Elisabetta Metafuni, Antonio De Vivo, Andrea Patriarca, Marta Venturi, Simona Raso, Amalia Figuera, Antonella Sau, Maria Bruna Greve, Milena Mirabile, Olga Mulas, Eloise Beggiato, Antonella Carbone, Martina Salvatori, Anna Paola Iori, Simona Sica, Wilma Barcellini, Bruno Fattizzo

Blood (2025) 146 (Supplement 1): 4665.

https://doi.org/10.1182/blood-2025-4665

Published: 2025

Journal Articles

Young (35 years) matched sibling donors for allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 4193.

https://doi.org/10.1182/blood-2025-4193

Published: 2025

Journal Articles

Study design of A phase 3, open-label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis

Blood (2025) 146 (Supplement 1): 4988.

https://doi.org/10.1182/blood-2025-4988

Published: 2025

Journal Articles

International, prospective study comparing nilotinib versus imatinib with early switch to nilotinib to obtain sustained treatment-free remission (TFR) in patients with chronic myeloid leukemia: The tfr rate at the end of follow-up

Blood (2025) 146 (Supplement 1): 905.

https://doi.org/10.1182/blood-2025-905

Published: 2025

Journal Articles

Impact of thiotepa dose in haploidentical allogeneic stem cell transplantation with thiotepa-busulfan-fludarabine conditioning for Acute Myeloid Leukemia in remission: A retrospective analysis of the EBMT acute leukemia working party

Blood (2025) 146 (Supplement 1): 5980.

https://doi.org/10.1182/blood-2025-5980

Published: 2025

Journal Articles

Aberrant lymphocytes are associated with increased inflammatory complications following CAR-T infusion

John Marra, Gina Zini, Nicoletta Pelliccioni, Eugenio Galli, Federica SORA, Silvia Bellesi, Marcello Viscovo, Ilaria Pansini, Alessandro Corrente, Giuseppe Leone, Stefan Hohaus, Simona Sica, Patrizia Chiusolo

Blood (2025) 146 (Supplement 1): 7690.

https://doi.org/10.1182/blood-2025-7690

Published: 2025

Journal Articles

Which inflammation matters? distinct risk signatures before CAR-T cell therapy and the role of inflamix

Ilaria Pansini, Eugenio Galli, Alessandro Corrente, Patrizia Chiusolo, Marcello Viscovo, Giuseppe Leone, Silvia Bellesi, Nicola Piccirillo, Stefan Hohaus, Federica SORA, Simona Sica

Blood (2025) 146 (Supplement 1): 7625.

https://doi.org/10.1182/blood-2025-7625

Published: 2025

Journal Articles

T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 114.

https://doi.org/10.1182/blood-2025-114

Published: 2025

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria - a Study on Behalf of Cmwp and Saawp of the EBMT

Blood (2024) 144 (Supplement 1): 4949.

https://doi.org/10.1182/blood-2024-203009

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Retrospective Multicenter Analysis on 285 Procedures Performed between 2000 and 2020

Blood (2024) 144 (Supplement 1): 2186.

https://doi.org/10.1182/blood-2024-194320

Published: 2024

Journal Articles

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 4944.

https://doi.org/10.1182/blood-2024-207391

Published: 2024

Journal Articles

Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT

Blood (2024) 144 (Supplement 1): 3570.

https://doi.org/10.1182/blood-2024-205455

Published: 2024

Journal Articles

CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

Blood (2024) 144 (Supplement 1): 3155.

https://doi.org/10.1182/blood-2024-207877

Published: 2024

Journal Articles

Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT

Blood (2024) 144 (Supplement 1): 2193.

https://doi.org/10.1182/blood-2024-208242

Published: 2024

Journal Articles

Aplastic Anemia in the Elderly: Treatment Patterns and Outcomes from an International Observational Study

Bruno Fattizzo, Carmelo Gurnari, Sabrina Giammarco, Antony Ricchiuti, Hussein Awada, Marta Bortolotti, Giacinto Luca Pedone, Francesco Versino, Dario Consonni, Roochi Trikha, Shreyans Gandhi, Simona Sica, Jaroslaw Maciejewski, Austin G. Kulasekararaj, Wilma Barcellini

Blood (2024) 144 (Supplement 1): 4076.

https://doi.org/10.1182/blood-2024-198321

Published: 2024

Journal Articles

Immunomodulatory Effect of Dasatinib Plus Blinatumomab Versus Ponatinib Plus Blinatumomab in Newly Diagnosed Ph + Acute Lymphoblastic Leukemia Patients

Michela Ansuinelli, Maria Stefania De Propris, Maria Cristina Puzzolo, Nadia Peragine, Tiziano Quacquarelli, Saveria Capria, Cristina Skert, Valentina Mancini, Simona Sica, Federico Lussana, Erika Borlenghi, Marco Cerrano, Daniele Vallisa, Valeria Cardinali, Sabina Chiaretti, Anna Guarini, Robin Foà

Blood (2024) 144 (Supplement 1): 838.

https://doi.org/10.1182/blood-2024-208827

Published: 2024

Journal Articles

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Blood (2024) 144 (Supplement 1): 2836.

https://doi.org/10.1182/blood-2024-210731

Published: 2024

Journal Articles

Serum Amyloid-a (SAA) Is an Optimal Acute Phase Protein for Cytokine Release Syndrome in CAR-T Patients Exposed to Tocilizumab

Eugenio Galli, Ilaria Pansini, Alessandro Corrente, Silvia Baroni, Patrizia Chiusolo, Simona Sica, Federica Sorà

Blood (2024) 144 (Supplement 1): 7245.

https://doi.org/10.1182/blood-2024-209861

Published: 2024

Journal Articles

Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis

Blood (2024) 144 (Supplement 1): 3559.

https://doi.org/10.1182/blood-2024-193992

Published: 2024

Journal Articles

Familial Predisposition in Myeloproliferative Neoplasms: An NGS-Driven Analysis

Luca Di Marino, Francesco Ramundo, Tanja Malara, Monica Rossi, Roberto Maggi, Federica Fosso, Silvia Betti, Elena Rossi, Giuseppe Leone, Simona Sica, Valerio De Stefano, Patrizia Chiusolo

Blood (2024) 144 (Supplement 1): 1763.

https://doi.org/10.1182/blood-2024-210896

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Early access program for danicopan (ALXN2040) as add-on treatment to eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH): Preliminary data from the Italian real-world survey.

Young (35 years) matched sibling donors for allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Study design of A phase 3, open-label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis

International, prospective study comparing nilotinib versus imatinib with early switch to nilotinib to obtain sustained treatment-free remission (TFR) in patients with chronic myeloid leukemia: The tfr rate at the end of follow-up

Impact of thiotepa dose in haploidentical allogeneic stem cell transplantation with thiotepa-busulfan-fludarabine conditioning for Acute Myeloid Leukemia in remission: A retrospective analysis of the EBMT acute leukemia working party

Aberrant lymphocytes are associated with increased inflammatory complications following CAR-T infusion

Which inflammation matters? distinct risk signatures before CAR-T cell therapy and the role of inflamix

T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria - a Study on Behalf of Cmwp and Saawp of the EBMT

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Retrospective Multicenter Analysis on 285 Procedures Performed between 2000 and 2020

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT

CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT

Aplastic Anemia in the Elderly: Treatment Patterns and Outcomes from an International Observational Study

Immunomodulatory Effect of Dasatinib Plus Blinatumomab Versus Ponatinib Plus Blinatumomab in Newly Diagnosed Ph + Acute Lymphoblastic Leukemia Patients

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Serum Amyloid-a (SAA) Is an Optimal Acute Phase Protein for Cytokine Release Syndrome in CAR-T Patients Exposed to Tocilizumab

Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis

Familial Predisposition in Myeloproliferative Neoplasms: An NGS-Driven Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only